Author

Tendai Kadiyirire

Observed name: T. Kadiyirire

Institution: King's College London

Observed institutions: Guy's Hospital, King's College London

OpenAlex ID: A5001760636

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

2019 · Ellie Rashidghamat, Tendai Kadiyirire, et al. · Journal of the American Academy of Dermatology · 105

Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa

2019 · Su M. Lwin, Farhatullah Syed, et al. · JCI Insight · 93

Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial

2019 · Wei-Li Di, Su M. Lwin, et al. · Human Gene Therapy · 42

Th2 response drives itch in dystrophic epidermolysis bullosa pruriginosa: A case-control study

2024 · Marieta Papanikolaou, Leigh Nattkemper, et al. · Journal of the American Academy of Dermatology · 10

287 Safety and early efficacy outcomes for lentiviral fibroblast gene therapy for recessive dystrophic epidermolysis bullosa

2019 · S.M. Lwin, F. Syed, et al. · Journal of Investigative Dermatology · 7

736 Intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa is safe, improves quality of life and reduces itch

2018 · E. Rashidghamat, T. Kadiyirire, et al. · Journal of Investigative Dermatology

738 Safety outcomes for first-in-man intradermal injections of lentiviral-engineered COL7A1-supplemented autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa

2018 · S.M. Lwin, F. Syed, et al. · Journal of Investigative Dermatology

Works count: 7

Citation count: 257

H-index: 5

I10-index: 4